According to the company, Duravyu 2.7mg demonstrated an early and sustained anatomical improvement mirroring BCVA results with a 68 micron reduction in CST. Full topline data is anticipated in Q1 of ...

Vikas Chopra, MD, led a course on minimally invasive glaucoma surgery (MIGS) and its impact on glaucoma care. He explained that MIGS enables ophthalmologists to intervene earlier and more safely, ...

Chronic therapy is essential for PCV patients, even after resolution of pigment epithelial detachment, to prevent recurrence. Faricimab and aflibercept show efficacy in DME, RVO, and nAMD, but not all ...

Brian Francis, MD, from the Doheny Eye Institute and the UCLA Department of Ophthalmology, shared insights on MIGS techniques ...

Jonathan Brugger, MD, shared insights on the correlation of central retinal vein occlusions, or branch retinal vein ...

Weijie Violet Lin, MD, presented findings from her research, which revealed that post-cross-linking complications were low ...

CBNS, such as turmeric, are natural anti-inflammatory and antioxidant agents that may confer benefits against AMD.

Duravyu, a sustained delivery therapy, targets wet AMD with biannual dosing, reducing treatment burden compared to frequent injections. The Phase 3 LUGANO and LUCIA trials aim for global regulatory ...

Low birth weight, blood transfusion, and necrotizing enterocolitis are significant risk factors for ROP in preterm infants. Postnatal weight gain may not accurately predict ROP development after ...

The study, conducted in 2022, highlights significant variations in glaucoma prevalence across different demographic groups, ...

In a paper presented at the American Academy of Ophthalmology annual meeting in Chicago, Jonathan Tan, a third year medical student at the Icahn School of Medicine at Mount Sinai detailed the study on ...

According to OKYO Pharma, OK-101 is the first drug candidate to enroll patients specifically diagnosed with neuropathic ...